About US
Contact us
-
GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new homeGlaxoSmithKline isn’t just making changes with itsU.S. operations. The company is nowexploring a new location for its global headquarters amid a historic business revamp. GSK will leave i2021/10/11
-
Viatris to close former Novartis site in California in January, lay off 75Viatris has been busy with cost cuts over the last year, including shuttering a plant in West Virginia that had served as a staple of its community.Now, a former Novartis plant in California—which My2021/10/11
-
AbbVie pressures Biohaven in migraine prevention with FDA approval for its CGRP blockbuster-to-be QuliptaTuesday, AbbVie said the FDA hasgreen-lightedits Qulipta, or atogepant, for prevention of episodic migraine. The go-ahead follows the landmark approval of Biohaven’s Nurtec ODT as the first oral anti2021/9/30
-
Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analystsMerck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-oncology megablockbuster Keytruda, bu2021/9/30
-
CDMO Lonza strikes deal with Allarity Therapeutics to manufacture cancer drug candidate dovitinibAllarity Therapeutics has worked diligently to develop Novartis’ failed cancer drug dovitinib. Now, as the Danish biotech anticipates the drug’s approval for metastatic renal cell carcinoma, it has l2021/9/27
-
Takeda breached its contract with AbbVie by failing to supply prostate cancer drug Lupron, court rulesTwo weeks after siding with Takeda in the Japanese pharma giant's spat with Lupron partner AbbVie, a Delaware judge has issued a separate ruling in favor of AbbVie. In his newestruling,Vi2021/9/27
-
Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analystBy this point in Biogen’s highly scrutinized rollout of Alzheimer’s drug Aduhelm, market watchers expected that thousands of U.S. patients would be on the treatment.That reportedly hasn’t been the ca2021/9/23
-
Novartis reshuffling doesn't portend a pullback from gene therapy, company saysTwo months ago, Novartis Gene Therapies chief Dave Lennon left the company to lead a biotech startup that is operating in stealth mode. It was with similar stealth that the unit Lennon formerly heade2021/9/23
-
With new facility and leadership, CDMO Genezen is stepping up to the big leaguesAs a young baseball player, moving from Cave Spring High School to Virginia Tech University was a challenge for Ray Kaczmarek. Three decades later, Kaczmarek finds himself in a similar situation. As2021/9/18
-
Gilead's slumping COVID-19 drug takes another hit with study showing no real benefitLast fall, Gilead Sciences was riding high with its sudden blockbuster Veklury, a failed Ebola drug repurposed for hospitalized COVID-19 patients. But less than a year later, doctors have increasingl2021/9/18